Literature DB >> 9234681

C/EBP factor suppression of inhibition of type II secreted phospholipase A2 promoter in HepG2 cells: possible role of single-strand binding proteins.

Q Fan1, M Paradon, C Salvat, G Bereziat, J L Olivier.   

Abstract

We previously reported that the type II secreted phospholipase A2 (sPLA2) promoter from positions (-326 to +20) ([-326;+20] promoter) is negatively regulated by two adjacent regulatory elements, C (-210 to -176) and D (-247 to -210). This study examines in greater detail the way in which this negative regulation operates. Successive 5' deletions of the [-326;+20] type II sPLA2 promoter indicated that the region upstream of position -195 inhibits the transcription activity sixfold in HepG2 cells but not in HeLa cells. Although the whole [-326;-176] region decreased the activity of a heterologous thymidine kinase promoter, this effect was orientation and position sensitive. C/EBP beta, C/EBP alpha, and C/EBP delta, which bind to element C, prevented the inhibition of promoter activity. Electrophoretic mobility shift experiments identified the binding of NF1-like proteins to the [-225;-218] site, which overlaps an insulin response-like sequence, 5'-TGTTTTG-3'. This sequence bound a factor which also recognized the promoters of the apolipoproteins C-III and A-II. Substitutions preventing the binding of this factor or the NF1-like proteins did not increase the transcription activity, but substitution in the [-217;-204] sequence blocked the transcription inhibition. This sequence did not bind any double-strand binding factor, but its antisense strand is critical for the binding of single-strand binding proteins to the [-232;-191] region. We therefore suggest that these single-strand binding proteins are involved in the inhibitory mechanism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234681      PMCID: PMC232277          DOI: 10.1128/MCB.17.8.4238

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

1.  Optimization of the CAT assay procedure by determining the initial rate of the enzymatic reaction.

Authors:  C Desbois; T Massé; J J Madjar
Journal:  Trends Genet       Date:  1992-09       Impact factor: 11.639

2.  Transcriptional activation and repression by cellular DNA-binding protein C/EBP.

Authors:  D Q Pei; C H Shih
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

3.  Cloning and characterisation of a nuclear, site specific ssDNA binding protein.

Authors:  M P Smidt; B Russchen; L Snippe; J Wijnholds; G Ab
Journal:  Nucleic Acids Res       Date:  1995-07-11       Impact factor: 16.971

4.  NF1-L is the DNA-binding component of the protein complex at the peripherin negative regulatory element.

Authors:  A D Adams; D M Choate; M A Thompson
Journal:  J Biol Chem       Date:  1995-03-24       Impact factor: 5.157

5.  YY1 represses rat serum amyloid A1 gene transcription and is antagonized by NF-kappa B during acute-phase response.

Authors:  S Y Lu; M Rodriguez; W S Liao
Journal:  Mol Cell Biol       Date:  1994-09       Impact factor: 4.272

6.  Purification and characterization of nuclear factors binding to the negative regulatory element D of human apolipoprotein A-II promoter: a negative regulatory effect is reversed by GABP, an Ets-related protein.

Authors:  P Cardot; D Pastier; J M Lacorte; M Mangeney; V I Zannis; J Chambaz
Journal:  Biochemistry       Date:  1994-10-11       Impact factor: 3.162

7.  Negative regulation of the vascular smooth muscle alpha-actin gene in fibroblasts and myoblasts: disruption of enhancer function by sequence-specific single-stranded-DNA-binding proteins.

Authors:  S Sun; E S Stoflet; J G Cogan; A R Strauch; M J Getz
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

8.  The androgen receptor is transcriptionally suppressed by proteins that bind single-stranded DNA.

Authors:  M E Grossmann; D J Tindall
Journal:  J Biol Chem       Date:  1995-05-05       Impact factor: 5.157

9.  Hepatic nuclear factor 3- and hormone-regulated expression of the phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein 1 genes.

Authors:  R M O'Brien; E L Noisin; A Suwanichkul; T Yamasaki; P C Lucas; J C Wang; D R Powell; D K Granner
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

10.  A silencer element for the lipoprotein lipase gene promoter and cognate double- and single-stranded DNA-binding proteins.

Authors:  Y Tanuma; H Nakabayashi; M Esumi; H Endo
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

View more
  5 in total

1.  Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone.

Authors:  Pragya Sharma; Shalini Thakran; Xiong Deng; Marshall B Elam; Edwards A Park
Journal:  J Biol Chem       Date:  2013-04-29       Impact factor: 5.157

Review 2.  Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease.

Authors:  Nhat D Quach; Robert D Arnold; Brian S Cummings
Journal:  Biochem Pharmacol       Date:  2014-06-04       Impact factor: 5.858

3.  Transcriptional Regulation of the Group IIA Secretory Phospholipase A2 Gene by C/EBPδ in Rat liver and its Relationship to Hepatic Gluconeogenesis during Sepsis.

Authors:  Rei-Cheng Yang; Chin Hsu; Tzu-Ying Lee; Kung-Kai Kuo; Shou-Mei Wu; Yen-Hsu Chen; Mei-Ling Ho; Xing-Hai Yao; Chia-Hsiung Liu; Maw-Shung Liu
Journal:  Emerg Med (Los Angel)       Date:  2013-08-28

4.  Functional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels.

Authors:  Holly J Exeter; Lasse Folkersen; Jutta Palmen; Anders Franco-Cereceda; Jackie A Cooper; Anastasia Z Kalea; Ferdinand Van't Hooft; Per Eriksson; Steve E Humphries; Philippa J Talmud
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

Review 5.  New developments in phospholipase A2.

Authors:  B Chaminade; F Le Balle; O Fourcade; M Nauze; C Delagebeaudeuf; A Gassama-Diagne; M F Simon; J Fauvel; H Chap
Journal:  Lipids       Date:  1999       Impact factor: 1.646

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.